Cargando…
Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
AIMS/INTRODUCTION: The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase‐4 (DPP‐4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic kidney disease. MATERIALS AND METHODS: The pre...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497591/ https://www.ncbi.nlm.nih.gov/pubmed/30136384 http://dx.doi.org/10.1111/jdi.12917 |
_version_ | 1783415488125075456 |
---|---|
author | Kitada, Munehiro Ogura, Yoshio Nitta, Kyoko Fujii, Mizue Kanasaki, Keizo Konishi, Kazunori Iida, Yasuo Nakagawa, Atsushi Koya, Daisuke |
author_facet | Kitada, Munehiro Ogura, Yoshio Nitta, Kyoko Fujii, Mizue Kanasaki, Keizo Konishi, Kazunori Iida, Yasuo Nakagawa, Atsushi Koya, Daisuke |
author_sort | Kitada, Munehiro |
collection | PubMed |
description | AIMS/INTRODUCTION: The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase‐4 (DPP‐4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic kidney disease. MATERIALS AND METHODS: The present study was a single‐arm, open‐label, observational study. A total of 23 patients, who had urinary albumin/creatinine ratios (UACR) ≥30 mg/gCr in their first urine in the early morning, and received other DPP‐4 inhibitors and renin‐angiotensin system inhibitors, switched to teneligliptin 20 mg/day. After switching to teneligliptin for 24 weeks, we evaluated changes in glycated hemoglobin (HbA1c), fasting plasma glucose levels, plasma DPP‐4 activity and UACR. RESULTS: HbA1c, fasting plasma glucose and UACR values showed no significant change after 24 weeks compared with baseline. However, plasma DPP‐4 activity was significantly reduced after 24 weeks (0.57 ± 0.26 nmol/min/mL, P = 0.012, vs baseline), compared with baseline (1.49 ± 1.73 nmol/min/mL), and there was a positive relationship between the change rate of plasma DPP‐4 activity (Δ%DPP‐4) for 24 weeks and the levels of plasma DPP‐4 activity (r = −0.5997, P = 0.0025) and fasting plasma glucose (r = −0.4235, P = 0.0440) at baseline. Additionally, the Δ%DPP‐4 for 24 weeks was significantly correlated to the change rate of UACR (r = 0.556, P = 0.0059). However, there was no relationship between Δ%DPP‐4 and ΔHbA1c (amount of HbA1c change). CONCLUSIONS: Switching to teneligliptin from other DPP‐4 inhibitors for 24 weeks reduces plasma DPP‐4 activity, which is associated with a reduction in albuminuria, independent of the change in glucose levels, in type 2 diabetes mellitus patients with diabetic kidney disease. |
format | Online Article Text |
id | pubmed-6497591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64975912019-05-07 Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease Kitada, Munehiro Ogura, Yoshio Nitta, Kyoko Fujii, Mizue Kanasaki, Keizo Konishi, Kazunori Iida, Yasuo Nakagawa, Atsushi Koya, Daisuke J Diabetes Investig Articles AIMS/INTRODUCTION: The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase‐4 (DPP‐4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic kidney disease. MATERIALS AND METHODS: The present study was a single‐arm, open‐label, observational study. A total of 23 patients, who had urinary albumin/creatinine ratios (UACR) ≥30 mg/gCr in their first urine in the early morning, and received other DPP‐4 inhibitors and renin‐angiotensin system inhibitors, switched to teneligliptin 20 mg/day. After switching to teneligliptin for 24 weeks, we evaluated changes in glycated hemoglobin (HbA1c), fasting plasma glucose levels, plasma DPP‐4 activity and UACR. RESULTS: HbA1c, fasting plasma glucose and UACR values showed no significant change after 24 weeks compared with baseline. However, plasma DPP‐4 activity was significantly reduced after 24 weeks (0.57 ± 0.26 nmol/min/mL, P = 0.012, vs baseline), compared with baseline (1.49 ± 1.73 nmol/min/mL), and there was a positive relationship between the change rate of plasma DPP‐4 activity (Δ%DPP‐4) for 24 weeks and the levels of plasma DPP‐4 activity (r = −0.5997, P = 0.0025) and fasting plasma glucose (r = −0.4235, P = 0.0440) at baseline. Additionally, the Δ%DPP‐4 for 24 weeks was significantly correlated to the change rate of UACR (r = 0.556, P = 0.0059). However, there was no relationship between Δ%DPP‐4 and ΔHbA1c (amount of HbA1c change). CONCLUSIONS: Switching to teneligliptin from other DPP‐4 inhibitors for 24 weeks reduces plasma DPP‐4 activity, which is associated with a reduction in albuminuria, independent of the change in glucose levels, in type 2 diabetes mellitus patients with diabetic kidney disease. John Wiley and Sons Inc. 2018-10-01 2019-05 /pmc/articles/PMC6497591/ /pubmed/30136384 http://dx.doi.org/10.1111/jdi.12917 Text en © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Kitada, Munehiro Ogura, Yoshio Nitta, Kyoko Fujii, Mizue Kanasaki, Keizo Konishi, Kazunori Iida, Yasuo Nakagawa, Atsushi Koya, Daisuke Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease |
title | Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease |
title_full | Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease |
title_fullStr | Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease |
title_full_unstemmed | Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease |
title_short | Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease |
title_sort | effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497591/ https://www.ncbi.nlm.nih.gov/pubmed/30136384 http://dx.doi.org/10.1111/jdi.12917 |
work_keys_str_mv | AT kitadamunehiro effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease AT ogurayoshio effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease AT nittakyoko effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease AT fujiimizue effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease AT kanasakikeizo effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease AT konishikazunori effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease AT iidayasuo effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease AT nakagawaatsushi effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease AT koyadaisuke effectofswitchingtoteneligliptinfromotherdipeptidylpeptidase4inhibitorsonglucosecontrolandrenoprotectionintype2diabetespatientswithdiabetickidneydisease |